Read the full story with photos at:
Over two decades ago, Otsuka Chairman Akihiko Otsuka implemented trainings to help promote female executives. Because of that vision, Otsuka Pharmaceutical now has 45 women whose positions are higher than division chiefs and five who are operating officers.
At this year’s Otsuka Diversity Forum held at Awaji Yumebutai International Conference Center (Hyogo Pref.), senior Otsuka female executives were invited to speak to 130 young and budding employees with diverse backgrounds about their own trials and tribulations and how they overcame their obstacles.
One faced cancer head on and with the support of her family and her determination, she overcame cancer, received her Ph.D. and is now the Director of Global Clinical Development; another moved to a foreign country in the middle of her Ph.D. program to lead a region with the lowest performance. But with passion, prioritization and sheer perseverance she succeeded in leading her region to becoming number one after three years and also finished her Ph.D.
An HR executive knew from when she was in college that she wanted to continue working as a researcher. She was able to do so because her mother and mother-in-law wanted her to succeed because they had wanted their own identity outside of the house. And one in middle management said she faced obstacles that once had overwhelmed her as a Medical Representative. She was asked to be responsible for a University Hospital with 500 physicians across 40 divisions. But with her husband’s support and her determination in breaking the barriers, she persevered by doing things no one else has done before therefore successfully managing her beat.
The goal for such a forum is to expose employees to other women’s plights in trying to get ahead and learn from their experiences as women executives in a male dominated field.
In his opening speech at the forum, Otsuka Pharmaceutical’s President, Representative Director, Taro Iwamoto, Ph.D., said, “As president, what I have aimed at for the past five years to promote what we call “creativity from this corner to that corner,” and not to copy other pharmaceutical companies.
The most important part of this concept is to employ people who continually innovate. Our company employs competitive staff in Asia and in the West for our overseas operations. There are much less gender barriers and our key elements of evaluation is innovation.” Dr. Iwamoto stated that the company goal is to increase the ratio of female executives to 50% by 2020.
Young male leaders were also invited to take part in the panel discussion. They shared what they are looking for in their team members but the consensus was that it’s not the gender that matters, but their staff’s passion and determination in succeeding in creating new products.
IBM Fellow Chieko Asakawa shared her journey of ups and downs to the audience.
Ms. Asakawa’s original dream was to become an Olympian as she was an active athlete in her school. But when she lost her vision in an accident in her junior high years, it didn’t derail her from living her life to its full potential and beyond. She loved outdoor activities and wanted to continue to do track, roller skate and scuba dive. That’s when she realized accessibility is needed for innovation that would allow her to keep her freedom. That began her accessibility research and development for the past two decades.
She said she may have lost her vision, but her hearing senses became more heightened allowing her to listen to spoken words that are three times faster than normal. She used her disadvantages to her advantage and pushed for technologies that would assist heightening other senses that may have been lost to some.
As for family life, Ms. Asakawa said when her two daughters were younger, they wanted their mother to be home more but that they now appreciate how much their mother has done to move forward the technology for the disabled. She said she still has lots of dreams to fulfill, like traveling to Africa and even learn about food and wine. To her, a disability does not mean an obstacle, but a spring board to something greater.
Read the full story with photos at:
Otsuka made its first international expansion in 1973, establishing Thai Otsuka Pharmaceutical (TOP). During that era, most Japanese pharmaceutical companies were focused on drug development in Western countries. However, Otsuka looked to its neighbors in the east and in 1981 became the first Japanese pharmaceutical company to establish a joint venture in China, China Otsuka Pharmaceutical Co., Ltd. Later, Otsuka headed westward to Europe and the US, offering its highly original products in the areas of pharmaceuticals, medical devices, nutraceuticals and cosmedics.
Today, Otsuka Pharmaceutical has over 20 affiliated research institutes and 139 production sites around the world. Otsuka employees are encouraged to take on creative challenges wherever they work, whether researching and developing products that promote health or supplying local markets.
Our pharmaceutical and nutraceutical products are sold in over 80 countries. For example, our central nervous system drug ABILIFY offers patients an excellent efficacy and side effect profile in disorders including schizophrenia and depression. ABILIFY is sold in 60 countries, is the seventh ranked prescription drug in global sales*1 and the number one ranked prescription drug in the United States.*2 Otsuka’s iconic beverage POCARI SWEAT, which replenishes critical electrolytes lost when sweating, is sold in 17 countries and regions and sales outside of Japan exceed domestic sales.
Overall, as the average Japanese pharmaceutical companies generate 35% of revenues internationally, Otsuka Pharmaceutical and its affiliates generate 62% and will continue to expand.
And on November 1st, 2013 Thai Otsuka Pharmaceutical (TOP) celebrated its 40th year of operation in a gala ceremony held at the Plaza Athenee Bangkok. The event brought together 220 of the company’s key stakeholders, local dignitaries and high-profile Otsuka delegates, while serving as an opportunity to renew its commitment as a leading pharmaceutical brand in Thailand.
The list of attendees included Japanese Ambassador to Thailand Shigekazu Sato; CEO Boonsithi Chokwatana from SAHA group; OPF Representative Director Tetsuji Iwamoto; OIAA’s Senior Operating Officer Eom Dae-sik and a number of previous TOP presidents.
Mr. Thanan Suntayodom, chairman, conveyed his overwhelming pride in having worked as a member of Thai Otsuka over the past 40 years and shared with the audience how Otsuka began its first step to overseas expansion.
“In 1965, Otsuka Pharmaceutical Co., Ltd. Japan had appointed Mr. Sakakibara (from the foreign trade department) to be the representative to bring I.V. solution products and find a distributing agency in Thai market and that was when he met my father, Charoen Suntayodom. Right after that, Charoen Bhaesaj Group started to import products from Otsuka. The product was well accepted by our customers for its high quality and for its good treatment.
As the sales volume grew rapidly, my father and Mr. Suwan Sirivikul flew and met Mr. Masahito Otsuka in 1971 to explain it was necessary to have a factory in the Thai market. After it was approved, a factory was established in Samut Sakorn province (about 50km from Bangkok) in 1973.”
In his congratulatory remarks, Japan Ambassador Sato expressed his sincere gratitude toward Thai Otsuka’s community service during Thailand’s worst flooding in 2011. Also, TOP President Motoyuki Sakiyama expressed his heart-felt gratitude toward its local employees, past and present, “We will become the best partner for our patients and clients in Thailand for another 40 prosperous years. Thai Otsuka is built upon Otsuka’s corporate philosophy which values innovative ideas, firm commitment to implementation as well as harmony with local culture.”